首页> 外文期刊>International journal of antimicrobial agents >Tigecycline in combination with other antimicrobials: a review of in vitro, animal and case report studies
【24h】

Tigecycline in combination with other antimicrobials: a review of in vitro, animal and case report studies

机译:替加环素与其他抗微生物药物联合:体外,动物和病例报告研究的回顾

获取原文
获取原文并翻译 | 示例
           

摘要

Tigecycline has been investigated in combination with other antibacterials against a wide range of sus_ceptible and multiresistant Gram-positive and Gram-negative bacteria. Combinations have been analysed in vitro, in animal models and in human case reports. In vitro, tigecycline combined with other antimicro_bials produces primarily an indifferent response (neither synergy nor antagonism). Nevertheless, synergy occurred when tigecycline was combined with rifampicin against 64-100% of Enterococcus spp., Strep_tococcus pneumoniae, E_terobacter spp. and Brucella melitensis isolates. Combinations of tigecycline with amikacin also showed synergy for 40-100% of Enterobacter spp., Klebsiella pneumoniae, Proteus spp. and Stenotrophomonas maltophilia isolates. Moreover, bactericidal synergisms occurred with tigecycline plus amikacin against problematic Acinetobacter baumannii and Proteus vulgaris, and with colistin against K. pneumoniae. Data from animal experiments and case reports, although limited, displayed consistent ben_eficial activity of tigecycline in combination with other antibacterials against multiresistant organisms, including vancomycin against penicillin-resistant S. pneumoniae in experimental meningitis, gentamicin against Pseudomonas aeruginosa in experimental pneumonia, daptomycin against Enterococcus faecium endocarditis, and colistin against K. pneumoniae bacteraemia and P. aeruginosa osteomyelitis. Antagonism was extremely rare in vitro and was not reported in vivo. Thus, tigecycline may be combined with a second antimicrobial as part of a combination regimen.
机译:已经研究了替加环素与其他抗菌素联合使用,以对抗多种易感和多重耐药的革兰氏阳性和革兰氏阴性细菌。已经在体外,动物模型和人类病例报告中分析了组合。在体外,替加环素与其他抗微生物药的结合主要产生无反应(既无协同作用也无拮抗作用)。然而,当替加环素与利福平联合使用时,针对64-100%的肠球菌,肺炎链球菌和大肠杆菌都具有协同作用。和布鲁氏菌分离株。替加环素与丁胺卡那霉素的组合还显示出对肠杆菌属,肺炎克雷伯菌,变形杆菌属的40-100%具有协同作用。和嗜麦芽窄食单胞菌的分离株。此外,替加环素加丁胺卡那霉素对有问题的鲍曼不动杆菌和寻常变形杆菌以及大肠菌素与肺炎克雷伯菌都有协同作用。来自动物实验和病例报告的数据尽管有限,但仍显示出替加环素与其他抗多种耐药生物的抗菌药具有一致的有益活性,包括对实验性脑膜炎的耐万古霉素,对青霉素耐药的肺炎链球菌,对实验性肺炎的庆大霉素对铜绿假单胞菌,对肠球菌的达托霉素粪便心内膜炎和大肠菌素抵抗肺炎克雷伯菌菌血症和铜绿假单胞菌骨髓炎。拮抗作用在体外极为罕见,体内没有报道。因此,替加环素可以与第二种抗菌素组合作为组合方案的一部分。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号